JP2005523334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523334A5 JP2005523334A5 JP2003587377A JP2003587377A JP2005523334A5 JP 2005523334 A5 JP2005523334 A5 JP 2005523334A5 JP 2003587377 A JP2003587377 A JP 2003587377A JP 2003587377 A JP2003587377 A JP 2003587377A JP 2005523334 A5 JP2005523334 A5 JP 2005523334A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical compound
- disorder
- group
- stress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000955 neuroendocrine Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000004064 dysfunction Effects 0.000 claims 4
- 239000003174 triple reuptake inhibitor Substances 0.000 claims 4
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 2
- 229940025084 amphetamine Drugs 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 230000001934 delay Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960000600 milnacipran Drugs 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 2
- 229960004425 sibutramine Drugs 0.000 claims 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 206010056557 Gulf war syndrome Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960002896 clonidine Drugs 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 229960002866 duloxetine Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 201000010076 persian gulf syndrome Diseases 0.000 claims 1
- 208000030062 persistent idiopathic facial pain Diseases 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000024335 physical disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000005062 synaptic transmission Effects 0.000 claims 1
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 claims 1
- 229960000488 tizanidine Drugs 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- 229960003991 trazodone Drugs 0.000 claims 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
Description
Claims (13)
- ストレス関連障害の発症を遅延または予防するか、または該ストレス関連障害の症状を軽減するための医薬の製造における、二重セロトニンノルエピネフリン再取り込みインヒビター（ＤＲＩ）および三重再取り込みインヒビター（ＴＲＩ）からなる群より選択される薬学的化合物の使用。
- 前記ＤＲＩ薬学的化合物が、セロトニンノルエピネフリン再取り込みインヒビター（ＳＮＲＩ）薬学的化合物またはノルエピネフリンセロトニン再取り込みインヒビター（ＮＳＲＩ）薬学的化合物である、請求項１に記載の使用。
- 前記ＤＲＩ薬学的化合物またはＴＲＩ薬学的化合物が、Ｎ−メチルＤ−アスパラギン酸（ＮＭＤＡ）アゴニスト活性を有する、請求項１に記載の使用。
- 前記ＳＮＲＩ薬学的化合物が、デュロキセチン、ベンラファキシンおよびそれらの組み合わせからなる群より選択される、請求項２に記載の使用。
- 前記ＮＳＲＩ薬学的化合物が、ミルナシプランである、請求項２に記載の使用。
- 前記ＴＲＩ薬学的化合物が、シブトラミンである、請求項１に記載の使用。
- 請求項１〜６のいずれか１項に記載の使用であって、前記薬学的化合物が、ニューロンチン、プレガバリン、プラミペキソール、Ｌ−ＤＯＰＡ、アンフェタミン、チザニジン、クロニジン、トラマドール、モルヒネ、三環系抗うつ薬、コデイン、カルバマゼピン、シブトラミン、アンフェタミン、バリウム、鎮静剤／睡眠薬およびトラゾドンからなる群より選択される薬剤と共投与される、使用。
- 前記ミルナシプランが、徐放性投薬処方物として処方される、請求項５に記載の使用。
- 前記薬学的化合物が、ストレス性事象の前、その間、またはその後に、投与される、請求項１〜８のいずれか１項に記載の使用。
- 前記薬学的化合物が、約２５ｍｇ／日〜約４００ｍｇ／日の量で、投与される、請求項１〜９のいずれか１項に記載の使用。
- 請求項１〜１０のいずれか１項に記載の使用であって、ここで、前記医薬が、片頭痛および緊張性頭痛、過敏性腸症候群、異型顔面痛、月経前不快気分障害、側頭下顎骨障害、非心臓性胸部痛、化学物質頻回暴露感度、慢性腰痛、間質性膀胱炎、慢性骨盤痛、ならびに湾岸戦争症候群からなる群より選択される機能的身体障害であるストレス関連障害を遅延させるか、予防するか、または緩和するためのものである、使用。
- 前記医薬が、パニック障害、強迫性障害、心的外傷後ストレス障害、全般性不安障害、および恐怖症からなる群より選択される不安性障害であるストレス関連障害を遅延させるか、予防するか、または緩和するためのものである、請求項１〜１０のいずれか１項に記載の使用。
- 前記医薬が、神経伝達機能不全、ＨＰＡ機能不全および神経内分泌機能不全からなる群より選択される２以上の経路における機能不全を薬学的に補正することによって、前記機能的身体障害を、遅延させるか、予防するか、または緩和するためのものである、請求項１１に記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37506802P | 2002-04-24 | 2002-04-24 | |
| US46428803P | 2003-04-18 | 2003-04-18 | |
| PCT/US2003/013247 WO2003090743A1 (en) | 2002-04-24 | 2003-04-24 | Prevention and treatment of functional somatic disorders, including stress-related disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009295495A Division JP2010070573A (ja) | 2002-04-24 | 2009-12-25 | ストレス関連障害を含む機能的身体障害の予防および処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523334A JP2005523334A (ja) | 2005-08-04 |
| JP2005523334A5 true JP2005523334A5 (ja) | 2006-06-15 |
Family
ID=29273017
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003587377A Withdrawn JP2005523334A (ja) | 2002-04-24 | 2003-04-24 | ストレス関連障害を含む機能的身体障害の予防および処置 |
| JP2009295495A Pending JP2010070573A (ja) | 2002-04-24 | 2009-12-25 | ストレス関連障害を含む機能的身体障害の予防および処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009295495A Pending JP2010070573A (ja) | 2002-04-24 | 2009-12-25 | ストレス関連障害を含む機能的身体障害の予防および処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20030232805A1 (ja) |
| EP (1) | EP1499309A4 (ja) |
| JP (2) | JP2005523334A (ja) |
| CN (1) | CN1662231A (ja) |
| AU (1) | AU2003225206B2 (ja) |
| CA (1) | CA2483093A1 (ja) |
| MX (1) | MXPA04011529A (ja) |
| WO (1) | WO2003090743A1 (ja) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| TW200402289A (en) * | 2002-05-17 | 2004-02-16 | Wyeth Corp | Methods of treating gastrointestinary and genitourinary pain disorders |
| AU2003227519A1 (en) * | 2002-05-30 | 2003-12-19 | Head Explorer A/S | The use of milnacipran for the treatment of tension-type headache |
| CA2500662A1 (en) * | 2002-10-03 | 2004-04-15 | Cypress Bioscience, Inc. | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders |
| US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| JP2006508978A (ja) * | 2002-11-19 | 2006-03-16 | イーライ・リリー・アンド・カンパニー | デュロキセチンを用いる胃腸障害の処置 |
| EP1908461B9 (fr) * | 2003-02-14 | 2011-08-31 | Pierre Fabre Medicament | Utilisation de l'énantiomère (1S, 2R) du milnacipran pour la préparation d'un médicament |
| FR2851163B1 (fr) * | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
| CA2529528A1 (en) * | 2003-06-20 | 2004-12-29 | Ronald Aung-Din | Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
| CA2542339A1 (en) * | 2003-09-09 | 2005-03-17 | Pfizer Products Inc. | Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors |
| CA2538412A1 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders |
| CA2611724C (en) * | 2005-06-10 | 2014-07-29 | Pierre Fabre Medicament S.A. | Stabilized milnacipran formulation |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| US20090054403A1 (en) * | 2007-07-23 | 2009-02-26 | Synosia Therapeutics | Treatment of Post-Traumatic Stress Disorder |
| US20100040680A1 (en) * | 2008-08-15 | 2010-02-18 | Felix Lai | Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation |
| EP2496079A4 (en) | 2009-11-06 | 2014-05-14 | Pierre Fabre Médicament Sas | NOVEL (1S, 2R) -2- (AMINOMETHYL) -N, N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE CRYSTALLINE FORMS |
| FR2978350B1 (fr) | 2011-07-28 | 2013-11-08 | Pf Medicament | Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu |
| WO2017087691A1 (en) | 2015-11-17 | 2017-05-26 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| WO2019094596A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| WO2020212952A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
| JP2023509800A (ja) * | 2020-01-10 | 2023-03-09 | コンシナンス セラピューティクス， インコーポレイテッド | 薬物の治療的組み合わせ及びそれらの使用方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2508035A1 (fr) * | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
| US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| US4761501A (en) * | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
| US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| JP2675573B2 (ja) * | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
| WO1994000114A1 (en) * | 1992-06-23 | 1994-01-06 | Sepracor Inc. | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine |
| US5352683A (en) * | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
| TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| EP0747348A4 (en) * | 1994-02-22 | 1999-07-07 | Asahi Chemical Ind | AMINOALKYLCYCLOPROPAN DERIVATIVES |
| ZA958725B (en) * | 1994-10-20 | 1997-04-16 | Lilly Co Eli | Treatment of disorders with duloxetine |
| AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| WO1997035584A1 (en) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating pain |
| CN1494907A (zh) * | 1996-03-25 | 2004-05-12 | 治疗疼痛的药物组合物 | |
| GB9617990D0 (en) * | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
| US6284794B1 (en) * | 1996-11-05 | 2001-09-04 | Head Explorer Aps | Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase |
| US5776969A (en) * | 1997-02-27 | 1998-07-07 | Eli Lilly And Company | Treatment of sleep disorders |
| WO1998050044A1 (en) * | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
| UA56257C2 (uk) * | 1997-09-23 | 2003-05-15 | Елі Ліллі Енд Компані | Спосіб лікування неадекватної визивної поведінки |
| JP2001520195A (ja) * | 1997-10-17 | 2001-10-30 | イーライ・リリー・アンド・カンパニー | 医薬の増強 |
| JP2002520353A (ja) * | 1998-07-16 | 2002-07-09 | マサチューセッツ インスティテュート オブ テクノロジー | ストレスの処置のための組成物 |
| ATE449603T1 (de) * | 1998-09-15 | 2009-12-15 | Lilly Co Eli | Verwendung von duloxetine zur behandlung von fibromyalgie |
| ATE269705T1 (de) * | 1998-10-27 | 2004-07-15 | Vela Pharmaceuticals Inc | Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen |
| ES2194536T3 (es) * | 1998-11-13 | 2003-11-16 | Lilly Co Eli | Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos. |
| US6323242B1 (en) * | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
| US6489341B1 (en) * | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
| ES2246485T3 (es) * | 1999-07-01 | 2006-02-16 | PHARMACIA & UPJOHN COMPANY LLC | (s,s)-reboxetina para tratar la incontinencia. |
| DE60027728T2 (de) * | 1999-08-04 | 2007-04-26 | Astellas Pharma Inc. | Stabile medizinische zusammensetzungen zur oralen verabreichung unter verwendung von eisenoxiden |
| WO2001012174A1 (en) * | 1999-08-13 | 2001-02-22 | Vela Pharmaceuticals Inc. | Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| AP2002002501A0 (en) * | 1999-10-07 | 2002-06-30 | Warner Lambert Co | Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog. |
| GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| US20010036943A1 (en) * | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| CA2364211A1 (en) * | 2000-12-05 | 2002-06-05 | Phillip Branch Chappell | Combination treatment for depression, anxiety and psychosis |
| WO2002053140A2 (en) * | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
| US20020147196A1 (en) * | 2001-04-05 | 2002-10-10 | Quessy Steven Noel | Composition and method for treating neuropathic pain |
| EA006396B1 (ru) * | 2001-04-19 | 2005-12-29 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си | Конденсированные бициклические аминокислоты |
| CA2475763A1 (en) * | 2002-02-12 | 2003-08-21 | Cypress Bioscience, Inc. | Methods of treating attention deficit/hyperactivity disorder (adhd) |
| AU2003298664A1 (en) * | 2002-11-20 | 2004-06-15 | Cypress Bioscience, Inc. | Treatment of cognitive dysfunctions' |
-
2003
- 2003-04-24 US US10/424,212 patent/US20030232805A1/en not_active Abandoned
- 2003-04-24 EP EP03721922A patent/EP1499309A4/en not_active Withdrawn
- 2003-04-24 JP JP2003587377A patent/JP2005523334A/ja not_active Withdrawn
- 2003-04-24 WO PCT/US2003/013247 patent/WO2003090743A1/en active Application Filing
- 2003-04-24 MX MXPA04011529A patent/MXPA04011529A/es active IP Right Grant
- 2003-04-24 CN CN038148455A patent/CN1662231A/zh active Pending
- 2003-04-24 AU AU2003225206A patent/AU2003225206B2/en not_active Ceased
- 2003-04-24 CA CA002483093A patent/CA2483093A1/en not_active Abandoned
-
2008
- 2008-09-19 US US12/233,790 patent/US20090105222A1/en not_active Abandoned
-
2009
- 2009-12-25 JP JP2009295495A patent/JP2010070573A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523334A5 (ja) | ||
| Racagni et al. | The pharmacological properties of antidepressants | |
| Predictable et al. | Side effects of antidepressants: an overview | |
| Bellingham et al. | Duloxetine: a review of its pharmacology and use in chronic pain management | |
| ES2638190T3 (es) | Métodos para tratar la dependencia | |
| JP2013544850A5 (ja) | ||
| JP2009511618A (ja) | 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用 | |
| US20090306137A1 (en) | Treatment for depressive disorders | |
| JP2016210798A5 (ja) | ||
| RU2008112192A (ru) | Милнаципран в качестве средства для продолжительного лечения синдрома фибромиалгии | |
| JP2011093924A (ja) | （−）−ベンラファキシン誘導体並びにその製造方法および使用方法 | |
| RU2005128548A (ru) | Применение (1s,2r) этантиомера милнаципрана для получения лекарственного средства | |
| JP2010535801A5 (ja) | ||
| CN102316863B (zh) | 5-苄基氨基水杨酸衍生物或其盐的医药用途 | |
| JP6406713B2 (ja) | 低用量薬剤によるうつ病および他の疾患の処置 | |
| WO2007047372A3 (en) | Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists | |
| JP5491475B2 (ja) | ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置 | |
| Christou et al. | The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update | |
| JP2015534563A5 (ja) | ||
| KR20060032598A (ko) | 세로토닌 재흡수 억제제 및 아고멜라틴의 조합 | |
| ES2625142T3 (es) | Usos terapéuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]-piperacina | |
| KR102266696B1 (ko) | 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제 | |
| WO2004100939B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| JP2011516604A (ja) | 鬱病患者の自殺行動の予防治療のためのミルナシプラン塩酸塩の（１ｓ，２ｒ）鏡像異性体の使用 | |
| JP5553955B2 (ja) | 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ |